Company news
Entrada Therapeutics, Inc. news in 2023
Entrada Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 21, 2023
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 6, 2023
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 20, 2023
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 6, 2023
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 9, 2023
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 7, 2023
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
July 31, 2023
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 9, 2023
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 3, 2023
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 28, 2023
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 26, 2023
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
February 8, 2023
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 8, 2023